Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced an enhanced clinical development strategy for IHL-42X, ...

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, ...

URO-1, Inc. is a life sciences company dedicated to advancing the tools and workflows used in soft tissue biopsy diagnostics.

A once-daily dose of a medication, which averaged 195 mg, produced blood levels significantly lower than those typically ...

As general contractor, SPIE will oversee the full project scope from planning to commissioning. This project will enhance grid reliability and support the integration of renewable energy, fully in ...

Welcome, everybody, to Ascom's 2025 Full Year Results Conference, and also welcome to the participants that we have on the webcast. Our plan for today according to the agenda, which maybe is going to ...

Our reader’s post cost-saving attempts have put him in a tricky tax position. Holly McKechnie looks at his options ...

The crisis had been brewing for several weeks on the Tottenham side, but the defeat against Newcastle served as the ...

Full year 2025 total revenues increased by 27% to US$376.1 million, driven by continued growth of RUCONEST® and rising demand for Joenja® (leniolisib) Fourth quarter 2025 total revenues increased by ...

Earnings call Ascom reported FY 2025 net revenue of CHF 292.1 million, up 4% in constant currency, and a 61% increase in EBITDA to CHF 34 million, with margin improving to 11.7%. Management guides for ...

Earnings call BioNTech delivered EUR 2.9 billion in 2025 revenue, surpassing guidance despite declining COVID-19 vaccine sales, aided by BMS collaboration payments. 2026 guidance targets EUR 2.0–2.3 ...